What Is Combination Product Characterization and Why Does It Matter?
Combination product characterization is the systematic process of identifying, analyzing, and documenting the chemical, physical, and biological properties of products that integrate a drug, device, and/or biological component into a single regulated entity. At Materials Metric, we help manufacturers navigate this complex testing landscape with confidence and regulatory clarity.
Regulatory agencies such as the FDA require thorough characterization data before approving any combination product. Consequently, manufacturers must address each constituent part โ the drug substance, the device material, and any biological component โ both individually and as a combined system. Without this data, submissions risk rejection or costly remediation cycles.
Furthermore, combination product characterization encompasses far more than simple chemical analysis. It integrates extractables and leachables profiling, biocompatibility evaluation, elemental impurity screening, and material identification into one coherent evidence package. As a result, the testing strategy must be carefully designed from the earliest stages of product development.
Key Takeaways
- Combination products contain a drug, device, and/or biological component โ each requiring dedicated characterization testing.
- Regulatory frameworks from the FDA, ISO, and USP govern how manufacturers must characterize these products.
- A well-designed characterization strategy covers chemistry, materials, extractables, leachables, and biocompatibility.
- Early-stage testing reduces costly late-development surprises and supports faster regulatory approval.
- Third-party laboratories provide independent, audit-ready data to strengthen regulatory submissions.
Combination product characterization: the comprehensive analytical and scientific evaluation of a product that combines drug, device, and/or biological components, conducted to identify material composition, chemical interactions, extractable and leachable substances, and biological safety risks in order to meet regulatory approval requirements.
Key fact: The FDA Office of Combination Products reports that combination products represent one of the fastest-growing and most complex product categories in the medical device and pharmaceutical industries, making robust characterization one of the leading drivers of regulatory submission quality.
What Defines a Combination Product Under Regulatory Frameworks?
Understanding what qualifies as a combination product is essential before building any characterization strategy. The FDA defines a combination product under 21 CFR Part 3 as a product comprising two or more regulated components โ drug/device, drug/biologic, device/biologic, or all three โ that are physically, chemically, or otherwise combined into a single entity.
The Three Main Combination Product Categories
Prefilled syringes are among the most commonly encountered examples in the industry. Additionally, drug-eluting stents, autoinjectors, and transdermal drug delivery patches all fall within this category. Each product type presents a distinct set of characterization challenges based on how the components interact.
Moreover, co-packaged products โ where a device and drug are packaged together but used separately โ also require combination product registration. For example, a surgical kit containing a topical drug and applicator device demands a coordinated review strategy. Therefore, manufacturers must map the constituent parts accurately before scoping their characterization work.
By contrast, cross-labeled products involve separately manufactured components with labeling that references the other component. Consequently, even without physical integration, regulators may require a unified characterization data package. Understanding the product type early helps define the testing scope precisely.
Primary Mode of Action and Lead Center Assignment
The FDA assigns combination products to a lead center โ CDER, CDRH, or CBER โ based on the product’s primary mode of action (PMOA). Specifically, if the drug component drives the primary therapeutic effect, CDER takes the lead. In addition, CDRH leads when the device component is the primary driver.
This assignment matters significantly for characterization. Furthermore, the lead center determines which regulatory pathways, guidances, and standards apply. For instance, CDRH-led products typically require ISO 10993 biocompatibility testing, while CDER-led products must satisfy USP and ICH requirements for drug substance and container-closure integrity.
Manufacturers should therefore request a Designation Request from the FDA’s Office of Combination Products when the PMOA is unclear. Doing so early avoids costly mid-development changes to the testing strategy. Overall, clarity on regulatory jurisdiction streamlines every subsequent characterization decision.
Why Is Combination Product Characterization Scientifically Challenging?
Combination product characterization poses unique scientific challenges precisely because no single regulatory framework fully covers all constituent components. Unlike a standalone medical device or a drug product, a combination product requires the simultaneous application of pharmaceutical chemistry, materials science, and toxicology expertise.
Material Interactions and Chemical Complexity
When a drug contacts a device component, new chemical interactions can occur. For example, plasticizers, adhesives, colorants, and processing aids in polymer-based device components may migrate into the drug substance over time. Consequently, this migration can alter drug potency, create new impurities, or introduce toxic leachables into the patient dose.
Furthermore, the drug formulation itself can affect device materials. Organic solvents in drug solutions may swell or degrade certain elastomers, altering extractable profiles significantly. Therefore, characterization must evaluate the drug-device interface under realistic, worst-case storage and use conditions.
Analytical tools such as GC-MS Analysis and HPLC Analysis are essential for identifying and quantifying these migrating chemical species. In addition, FTIR Analysis provides material identification data that helps trace the source of unexpected chemical signals. Together, these techniques build a robust chemical picture of the product system.
Biological Safety Considerations Unique to Combination Products
Combination products often involve prolonged or intimate patient contact, raising the stakes for biocompatibility evaluation. Importantly, the ISO 10993 series โ specifically ISO 10993-18 Chemical Characterization โ requires a chemistry-based risk assessment before any in vivo testing. This chemical characterization step is therefore central to the entire biological evaluation process.
In addition, toxicological risk assessment (TRA) requires comparing identified leachables against established threshold of toxicological concern (TTC) values. When leachables exceed TTC limits, additional biological testing becomes necessary. Consequently, early chemical characterization data directly controls the scope and cost of subsequent biocompatibility studies.
Materials Metric’s Biocompatibility & Toxicity Testing services are specifically designed to address these compound challenges. Furthermore, our team integrates chemical characterization findings with toxicological risk assessments to produce complete, submission-ready biological evaluation reports. This integrated approach saves manufacturers significant time and resources.
Regulatory Overlap and Dual Compliance Requirements
One of the most difficult aspects of combination product characterization involves satisfying two or more regulatory frameworks simultaneously. For instance, a prefilled autoinjector must comply with both ICH Q3D elemental impurity requirements for drugs and ISO 10993-18 chemical characterization requirements for the device container. These two standards use different analytical thresholds and risk assessment methodologies.
Additionally, USP requirements โ such as USP General Chapter <232> Elemental Impurities โ must be addressed for any drug-containing combination product. However, the device component may introduce elemental impurities through entirely different pathways than typical drug manufacturing. Therefore, a single unified analytical strategy must bridge both frameworks efficiently.
Manufacturers benefit greatly from working with a laboratory that understands both pharmaceutical and device regulatory contexts. Specifically, Scientific & Technical Consulting from experienced analytical chemists can map the applicable standards to the actual product design. Overall, this planning step prevents redundant testing and closes compliance gaps before they become regulatory issues.
What Analytical Methods Support Combination Product Characterization?
Effective combination product characterization depends on deploying the right analytical techniques in the right sequence. No single method captures all the required data. Instead, a well-designed testing battery combines spectroscopic, chromatographic, microscopic, and thermal techniques to build a complete material and chemical profile.
Spectroscopic Techniques for Material Identification
Spectroscopic methods form the backbone of any combination product characterization program. FTIR Analysis identifies polymer types, functional groups, and contaminants on material surfaces with high specificity. In addition, Raman Spectroscopy complements FTIR by analyzing aqueous samples and thin films that challenge infrared techniques.
Furthermore, XPS Analysis provides detailed surface chemistry data โ particularly useful for coated device components in drug-device combinations. Similarly, XRF Analysis delivers rapid, non-destructive elemental screening across a wide range of materials. Together, these tools provide a multi-layered view of the product’s material composition.
Chromatographic Methods for Chemical Purity and Leachables
Chromatographic techniques are indispensable for extractables and leachables profiling. GC-MS Analysis excels at detecting and identifying volatile and semi-volatile organic compounds in device extracts. Meanwhile, HPLC Analysis covers non-volatile and polar compounds that GC-MS cannot resolve effectively.
In particular, NMR Spectroscopy offers powerful structural elucidation for unknown leachable compounds identified by chromatographic screening. Consequently, NMR is frequently used to confirm peak identities and support toxicological risk assessments with confident structural data. This confirmation step is critical when leachables approach or exceed safety thresholds.
For elemental impurities, inductively coupled plasma mass spectrometry (ICP-MS) and ICP-OES provide the sensitivity and selectivity required by ICH Q3D and USP General Chapter <232>. Moreover, our Chemical Purity & Contaminant Screening services cover these elemental techniques alongside organic impurity analysis. As a result, manufacturers receive a complete impurity profile from a single laboratory partner.
Microscopic and Structural Analysis Techniques
Physical characterization of combination product materials requires high-resolution microscopic techniques. SEM Analysis reveals surface morphology, particulate contamination, and interface characteristics at the micron scale. Furthermore, energy-dispersive X-ray spectroscopy (EDS) coupled with SEM provides localized elemental mapping of those features.
For crystalline materials in drug-device combinations, XRD Analysis confirms phase composition and polymorph identity. Additionally, DSC Testing characterizes thermal transitions such as melting points, glass transition temperatures, and crystallinity โ all of which influence drug release and device performance. These thermal and structural data points are increasingly required in regulatory submissions for combination products.
Quick note: A well-scoped analytical test plan for combination product characterization typically includes at least four to six complementary techniques spanning spectroscopy, chromatography, microscopy, and thermal analysis. Using a single method in isolation risks missing critical chemical interactions or impurities that only emerge through orthogonal approaches.
Our Chemical & Elemental Characterization services integrate all of these techniques into a single coordinated program. Specifically, we align method selection with the applicable regulatory frameworks โ ISO 10993-18, ICH Q3D, and USP โ to ensure the data fully supports the submission. Furthermore, our Chemical & Analytical Testing capabilities allow us to execute the full characterization battery under one quality system, simplifying data traceability and audit management.
By comparison, using multiple disconnected laboratories for different analytical techniques creates coordination risks and data integrity challenges. Therefore, working with a single expert partner for the full combination product characterization scope offers significant practical and regulatory advantages.
Moreover, early engagement with the analytical laboratory during product design allows the testing strategy to evolve alongside the design. Consequently, last-minute testing surprises โ which are a leading cause of submission delays โ become far less likely when characterization is built into the development timeline from the start.
How Does Elemental Impurity Testing Fit Into Combination Product Characterization?
Elemental impurity testing plays a central role in combination product characterization. Residual metals from device components, processing equipment, and raw materials can migrate into the drug product and harm patients. Therefore, manufacturers must apply a structured, risk-based analytical approach that satisfies both pharmaceutical and device standards simultaneously.
ICP-MS and ICP-OES: The Gold Standards for Elemental Analysis
Inductively coupled plasma mass spectrometry (ICP-MS) delivers exceptional sensitivity for elemental impurity detection. Specifically, ICP-MS can quantify elements at parts-per-trillion (ppt) levels โ a critical capability when oral daily exposure (ODE) limits are extremely tight. Consequently, this technique is the preferred tool for meeting ICH Q3D and USP Elemental Impurities requirements in drug-containing combination products.
Inductively coupled plasma optical emission spectrometry (ICP-OES) complements ICP-MS for higher-concentration elemental work. Furthermore, ICP-OES handles complex matrices more robustly in some scenarios, making it ideal for device component digests. Together, these two techniques cover the full periodic table of concern across both pharmaceutical and device constituent parts.
Atomic Absorption Spectrometry as a Targeted Method
Atomic absorption spectrometry (AAS) offers a cost-effective, targeted approach for specific elemental analyses. For example, graphite furnace AAS (GFAAS) achieves excellent detection limits for elements such as lead, cadmium, and arsenic. However, AAS analyzes only one element per run, making it less efficient than ICP-MS for broad-spectrum screening programs.
Manufacturers often use AAS to confirm ICP-MS findings for specific elements of regulatory concern. Additionally, AAS serves as a validation reference method when developing ICP-based procedures. Overall, a combination of ICP-MS, ICP-OES, and AAS provides comprehensive elemental coverage for any combination product characterization program.
Linking Elemental Data to Toxicological Risk Assessment
Raw elemental concentration data alone does not satisfy regulatory requirements. Moreover, manufacturers must convert those concentrations into patient daily exposures and compare them against ICH Q3D permitted daily exposures (PDEs). Consequently, the laboratory must understand route-of-administration adjustments and the specific contact duration of the combination product.
Our Chemical & Elemental Characterization services include not only analytical measurement but also expert interpretation aligned with regulatory limits. Furthermore, our team integrates elemental findings into the broader toxicological risk assessment required by ISO 10993-18. This end-to-end approach ensures that analytical data translates directly into defensible regulatory conclusions.
| Technique | Best Application | Detection Range | Key Advantage |
|---|---|---|---|
| ICP-MS | Trace elemental impurities in drug/device extracts | ppt to ppb | Ultra-low detection limits; multi-element |
| ICP-OES | Major and minor elemental analysis in complex matrices | ppb to ppm | Wide dynamic range; robust for high-matrix samples |
| GFAAS | Targeted single-element confirmation (Pb, Cd, As) | ppb to ppt | High sensitivity; low instrument cost |
| XRF | Non-destructive bulk elemental screening of solid materials | ppm to % | Non-destructive; fast screening |
Combination Product Characterization Across Key Industry Applications
Combination product characterization requirements vary considerably depending on the product type and its intended clinical use. Understanding industry-specific expectations helps manufacturers scope testing efficiently and avoid both under-testing and over-testing. The following sections outline the most common application areas and their distinct characterization demands.
Drug-Device Combinations in Pharmaceutical Development
Prefilled syringes, autoinjectors, and inhaled drug-device systems represent the largest category of pharmaceutical combination products. In particular, container-closure integrity, extractables and leachables profiling, and elemental impurity testing are all mandatory for these systems. Furthermore, drug compatibility studies must confirm that device materials do not degrade the active pharmaceutical ingredient over the product shelf life.
Published research in ScienceDirect analytical journals consistently highlights how multi-technique characterization strategies improve confidence in drug-device compatibility conclusions. Specifically, combining GC-MS, HPLC, and ICP-MS data provides a far more complete picture than any single technique alone. Our Chemical & Analytical Testing services are structured precisely to support this multi-technique approach.
Implantable and Long-Term Contact Medical Devices With Drug Components
Drug-eluting stents, drug-coated orthopedic implants, and intravitreal drug delivery systems involve extended or permanent patient contact. As a result, biocompatibility requirements are among the most stringent in the combination product space. Specifically, ISO 10993 testing must cover cytotoxicity, sensitization, systemic toxicity, and implantation โ all informed by chemistry data.
Additionally, the extended contact duration amplifies leachable exposure risks significantly. Even low-concentration leachables become safety concerns when a patient is exposed continuously over years. Consequently, the analytical detection limits and toxicological risk thresholds applied to these products must reflect their unique exposure profiles.
Our Biocompatibility & Toxicity Testing team works closely with combination product developers to design studies that address these extended-exposure scenarios comprehensively. Moreover, we integrate chemical characterization data with biological evaluation findings into a single coherent regulatory package.
Transdermal Delivery Systems and Topical Drug-Device Combinations
Transdermal patches combine adhesive device materials with drug reservoirs in intimate skin contact. Characterization for these products must address adhesive polymer extractables, drug permeation enhancer compatibility, and backing film leachables simultaneously. Therefore, the analytical scope is broader than for many other combination product types.
Furthermore, skin sensitization potential of leachables requires early assessment using toxicological risk analysis based on chemistry data. By identifying high-concern chemicals early, manufacturers can reformulate or substitute materials before clinical studies begin. This proactive approach significantly reduces late-stage development risk and regulatory uncertainty.
Building a Robust Quality Assurance Framework for Combination Product Characterization
Strong quality assurance practices underpin every reliable combination product characterization program. Regulatory agencies scrutinize not only the test results but also the systems that generated them. Consequently, manufacturers must ensure their laboratory partners operate under validated methods, traceable standards, and documented quality management systems.
Method Development and Validation for Combination Products
Standard pharmacopeial or compendial methods do not always exist for combination product characterization challenges. In many cases, laboratories must develop custom extraction procedures, tailored analytical methods, and product-specific sample preparation protocols. Therefore, method development and validation become critical steps before generating any regulatory submission data.
Validation parameters โ including specificity, linearity, accuracy, precision, detection limit, and quantitation limit โ must be formally demonstrated for each analytical method. Furthermore, validation must be conducted under a quality system that meets ICH Q2(R1) guidance. Our Method Development & Validation services ensure that every characterization method we employ generates data that regulators can rely on with confidence.
Documentation, Data Integrity, and Audit Readiness
Regulatory submissions for combination products require comprehensive, traceable documentation. Specifically, raw data, instrument logs, calibration records, and analyst training records must all be accessible and auditable. Additionally, data integrity principles โ including ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate) โ apply to all generated characterization data.
Third-party laboratories with ISO 17025 accreditation provide an independent quality assurance layer that regulatory agencies recognize. Moreover, working with an accredited partner simplifies your audit preparation and demonstrates a commitment to scientific rigor. Our Scientific & Technical Consulting team can also help you design an internal documentation framework that aligns with FDA expectations for combination product submissions.
Establishing a Testing Timeline Aligned With Development Milestones
Timing characterization activities correctly prevents costly development delays. Importantly, extractables studies on device components should begin during early design stages, long before clinical material is committed. Consequently, any chemistry-driven material changes can occur before the design is locked โ saving both time and money.
A phased testing approach works well for most combination product programs. Initially, broad screening studies identify the full chemical space of concern. Subsequently, targeted leachables studies under real-world conditions confirm actual patient exposure levels. Finally, toxicological risk assessments close the loop and define whether additional biological testing is required.
Quick note: Starting combination product characterization after design freeze significantly increases the risk of uncovering material incompatibilities too late to address without costly design changes or testing repeats. Engage your analytical laboratory partner at the earliest design stages possible.
Frequently Asked Questions About Combination Product Characterization
What is the difference between extractables and leachables in combination product characterization?
Extractables are chemical compounds that migrate from device or packaging materials under aggressive laboratory conditions โ typically using exaggerated solvents, temperatures, or contact times. Leachables, by contrast, are the subset of those compounds that actually migrate into the drug product under normal storage and use conditions. Therefore, extractables studies define the worst-case chemical space, while leachables studies confirm real-world patient exposure.
Which regulatory standards govern combination product characterization?
Several overlapping standards apply, depending on the product type and lead regulatory center. Key frameworks include FDA 21 CFR Part 3 for classification, ISO 10993-18 for chemical characterization of device components, ICH Q3D for elemental impurities, and USP General Chapters <232> and <233> for elemental impurity testing in drugs. Furthermore, FDA guidance documents specifically addressing combination products โ such as the 2016 Current Good Manufacturing Practice guidance โ add additional compliance requirements.
When should combination product characterization testing begin during development?
Ideally, manufacturers should initiate extractables screening during the material selection and early design phase. Consequently, data from these early studies informs both material selection decisions and the risk assessment framework. Waiting until late-stage development or design freeze to begin characterization significantly increases the risk of expensive surprises that delay regulatory submission.
Can a single laboratory handle both pharmaceutical and device characterization requirements?
Yes โ and working with a single expert partner offers significant advantages. Specifically, a laboratory experienced in both pharmaceutical and medical device analytical requirements can design a unified testing strategy that satisfies both regulatory frameworks simultaneously. Moreover, single-source testing simplifies data traceability, reduces coordination burden, and produces a coherent evidence package that is easier for regulators to review.
How does toxicological risk assessment (TRA) connect to chemical characterization data?
TRA uses the chemical identity and concentration data generated during characterization to calculate patient daily exposure for each identified leachable or impurity. Specifically, those exposures are then compared against established safety thresholds โ such as the threshold of toxicological concern (TTC) or ICH Q3D permitted daily exposures. When exposure levels exceed thresholds, additional biological testing is triggered. Therefore, the quality and completeness of the chemical characterization data directly determines the scope and cost of the biological safety program.
What should manufacturers look for when selecting a combination product characterization laboratory?
Key selection criteria include ISO 17025 accreditation, demonstrated experience with both pharmaceutical and medical device standards, a broad suite of in-house analytical instrumentation, and validated methods for extractables and leachables profiling. Furthermore, the laboratory should offer toxicological risk assessment capabilities and regulatory consulting support. Importantly, a partner that can deliver integrated analytical and regulatory strategy โ rather than just raw data โ adds the greatest value to your development program.
Conclusion
Combination product characterization is one of the most technically demanding and regulatory-critical activities in modern pharmaceutical and medical device development. Successfully navigating it requires deep analytical expertise, a multi-technique testing strategy, and a thorough understanding of overlapping regulatory frameworks. Furthermore, it demands disciplined quality assurance and early integration into the product development timeline.
The consequences of inadequate characterization are significant. Regulatory submissions risk rejection, clinical studies may be delayed, and patient safety can be compromised when chemical interactions and leachable exposures go undetected. Therefore, investing in a rigorous, well-planned characterization program from the earliest development stages is both a scientific and a business imperative.
At Materials Metric, our team brings together analytical chemistry, materials science, and regulatory expertise to support every stage of your combination product characterization program. Specifically, we offer fully integrated services โ from method development and extractables screening through elemental impurity testing and biocompatibility assessment โ all under a single, audit-ready quality system. Moreover, our Method Development & Validation capabilities ensure that every data point we generate meets the evidentiary standards regulators expect.
Whether you are developing a prefilled autoinjector, a drug-eluting implant, or a transdermal delivery system, we have the instruments, expertise, and regulatory knowledge to support your characterization goals. Additionally, our Scientific & Technical Consulting service helps manufacturers design testing strategies that are both scientifically sound and efficiently scoped โ avoiding both gaps and unnecessary redundancy.
Ready to build a defensible, submission-ready combination product characterization program? Contact Materials Metric today to speak with our technical team about your specific product, regulatory pathway, and testing requirements. We look forward to supporting your path from development to regulatory approval.
Related Posts from Materials Metric
Explore more insights from our team of materials scientists and analytical experts:
